Administration of Esmolol improves clinical outcomes of patients undergoing cardiac surgeries

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300072428

Enrollment

Unknown

Registered

2023-06-13

Start date

2023-07-01

Completion date

Unknown

Last updated

2023-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cardiac diseases

Interventions

esmolol group:administration of esmolol

placebo group:saline

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age > 18 years old; 2. Cardiac function level 1-3; 3. Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Allergic to Esmolol; 2. Multiple organ insufficiency; 3. Arrhythmia; 4. Esmolol was used within 7 days before surgery.

Design outcomes

Primary

Measure	Time frame
heart rate;	—

Secondary

Measure	Time frame
ICU stay;postoperative hospitalization;other drug dose;anxiety;delilrium;	—

Countries

China

Contacts

Public ContactSun Liangong

Provincial Hospital Affiliated to Shandong First Medical University

deepblue1229@163.com+86 187 5315 7305

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026